Posted by Michael Wonder on 27 Jun 2021
BioMarin receives positive CHMP opinion in Europe for vosoritide for the treatment of children with achondroplasia from age 2 until growth plates close
25 June 2021 - Temporary Authorization for Use (ATU) granted in France to allow access and reimbursement of vosoritide to begin immediately.
BioMarin Pharmaceutical announced today that the CHMP has adopted a positive opinion recommending marketing authorisation for vosoritide, a once daily injection analog of C-type natriuretic peptide to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height.
